ETOH Tomomaro | Department of Obstetrics and Gynecology, Kinki University School of Medicine
スポンサーリンク
概要
- ETOH Tomomaroの詳細を見る
- 同名の論文著者
- Department of Obstetrics and Gynecology, Kinki University School of Medicineの論文著者
関連著者
-
Koike Eiji
Department Of Obstetrics And Gynecology Kinki University School Of Medicine
-
Koike Eiji
Department Of Gynecology Kinki University School Of Medicine
-
HOSHIAI Hiroshi
Department of Obstetrics and Gynecology, Kinki University School of Medicine
-
WATANABE Yoh
Department of Obstetrics and Gynecology, Kinki University School of Medicine
-
Hoshiai H
Department Of Obstetrics And Gynecology Kinki University School Of Medicine
-
Watanabe Yoh
Kinki Univ. School Of Medicine Osaka Jpn
-
Watanabe Yoh
Department Of Obstetrics And Gynecology Kinki University School Of Medicine
-
ETOH Tomomaro
Department of Obstetrics and Gynecology, Kinki University School of Medicine
-
Etoh Tomomaro
Department Of Obstetrics And Gynecology Kinki University School Of Medicine
-
Hoshiai Hiroshi
Department Of Obstetrics And Gynaecology Kinki University School Of Medicine
-
Hoshiai Hiroshi
Department Of Obstetric And Gynecology Kinki University Faculty Of Medicine
-
Hoshiai Hiroshi
Department Of Obstetricts And Gynecology Kinki University Faculty Of Medicine
-
NAKAI Hidekatsu
Department of Obstetrics and Gynecology, Kinki University School of Medicine
-
MIZUNO Yoshiaki
Department of Applied Physics,Nagoya University
-
Mizuno Yoshiaki
Department Of Applied Physics Nagoya University
-
Nakai Hidekatsu
Department Of Obstetrics And Gynecology Kinki University School Of Medicine
-
WANG Wei-Min
Department of Obstetrics and Gynecology, Kinki University School of Medicine
-
Wang Wei-min
Department Of Obstetrics And Gynecology Kinki University School Of Medicine
-
Mizuno Yoshiaki
Department Of Obstetrics And Gynecology Kinki University School Of Medicine
著作論文
- Phase II study of single-agent gemcitabine in heavily pretreated Japanese patients with recurrent ovarian cancer
- Feasibility study of oral cyclophosphamide salvage therapy for the treatment of heavily pretreated patients with recurrent epithelial ovarian cancer